Daily News Podcast

New cell-free DNA assays hold promise for lung cancer screening


 

A set of blood-based assays that search for abnormalities in cell-free DNA show moderately good sensitivity for detecting early-stage lung cancer. Also today, the FDA approves rituximab for the treatment of pemphigus vulgaris (prescribing information), obstructive sleep apnea with worsening hypoxemia raises metabolic syndrome risk, and the Department of Justice won’t defend the Affordable Care Act from a lawsuit. Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

High testosterone in postmenopausal women may add CVD risk
MDedge Hematology and Oncology
Severity of sepsis-associated coagulopathy predicts hospital mortality
MDedge Hematology and Oncology
ACS: Screen for colon cancer at 45
MDedge Hematology and Oncology
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
MDedge Hematology and Oncology
What is causing my patients’ macrocytosis?
MDedge Hematology and Oncology
Hip pain predicts arthritis mortality beyond comorbidities
MDedge Hematology and Oncology
Prostate cancer risk before age 55 higher for black men
MDedge Hematology and Oncology
Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Hematology and Oncology
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Hematology and Oncology
Suicide rate jumps 30%
MDedge Hematology and Oncology